UNITED LAB(03933),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

03933 UNITED LAB

Not Yet Opened 02-04 16:08:25

11.850

+0.040

+0.34%

High11.980	Low11.570	Vol5.97M
Open11.870	D1 Closing11.810	Amplitude3.47%
Mkt Cap23.38B	Tradable Cap23.38B	Total Shares1.97B
T/O70.21M	T/O Rate0.30%	Tradable Shares1.97B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"UNITED LAB","latestPrice":11.85,"timestamp":1770192505005,"preClose":11.81,"halted":0,"volume":5966800,"delay":0,"changeRate":0.0033869602032175396,"floatShares":1973000000,"shares":1973000000,"eps":1.463938,"marketStatus":"Not Yet Opened","change":0.04,"latestTime":"02-04 16:08:25","open":11.87,"high":11.98,"low":11.57,"amount":70214134,"amplitude":0.034716,"askPrice":11.85,"askSize":16000,"bidPrice":11.81,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":1.702,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":0,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":11.81,"dividendRate":0.041522,"openAndCloseTimeList":[[1770168600000,1770177600000],[1770181200000,1770192000000]],"volumeRatio":0.8658488341364001,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933","defaultTab":"news","newsList":[{"id":"2608987076","title":"BRIEF-United Laboratories International Gets Approval For Clinical Trial Of UBT251 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2608987076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608987076?lang=en_us&edition=fundamental","pubTime":"2026-02-03 23:07","pubTimestamp":1770131220,"startTime":"0","endTime":"0","summary":"BRIEF-United Laboratories International Gets Approval For Clinical Trial Of UBT251 InjectionFeb 3  - United Laboratories International Holdings Ltd 3933.HK:APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION FOR OSA FROM NMPAFurther company coverage: 3933.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ07J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2608875924","title":"United Laboratories Gets China Nod for Unit's Sleep Apnea Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608875924","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608875924?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:24","pubTimestamp":1770121498,"startTime":"0","endTime":"0","summary":"The United Laboratories International  obtained approval for the clinical trial application of UBT251 injection from  China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug was developed by The United Bio-Technology , a unit of the firm, and is indicated to treat moderate to severe obstructive sleep apnea with obesity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","UBCP","03933","BK4211"],"gpt_icon":0},{"id":"1145231603","title":"The United Laboratories (Stock Code: 3933) Announces Approval for UBT251 Injection Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1145231603","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145231603?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:45","pubTimestamp":1770115506,"startTime":"0","endTime":"0","summary":"On 2 February 2026, The United Laboratories International Holdings Limited (Stock Code: 3933) reported that its wholly owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd., gained approval...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"gpt_icon":0},{"id":"1178930497","title":"Federal Pharmaceutical (03933): UBT251 Injection Receives Implied Clinical Trial Approval for OSA Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1178930497","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178930497?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:44","pubTimestamp":1770115462,"startTime":"0","endTime":"0","summary":"Federal Pharmaceutical (03933) announced that on February 2, 2026, its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., obtained implied clinical trial approval from China's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2608822750","title":"TUL erhält Zulassung für klinische Studie mit UBT251-Injektion bei OSA in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822750","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608822750?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:41","pubTimestamp":1770115269,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL7sMZrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2608822235","title":"United Laboratories International - Approval for Clinical Trial of Ubt251 Injection for Osa From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608822235?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:40","pubTimestamp":1770115253,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ07J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2606713830","title":"FDA Approves IND Application for TUL108 Injection from The United Laboratories","url":"https://stock-news.laohu8.com/highlight/detail?id=2606713830","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606713830?lang=en_us&edition=fundamental","pubTime":"2026-01-28 19:40","pubTimestamp":1769600436,"startTime":"0","endTime":"0","summary":"The United Laboratories International Holdings Limited announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd., has received approval from the U.S. Food and Drug Administration  for its investigational new drug  application for TUL108 for injection. TUL108 is a novel, broad-spectrum β-lactamase inhibitor developed by the company, intended for the treatment of infections caused by Gram-negative or Gram-positive bacteria, including complicated urinary tract infections, complicated intra-abdominal infections, pulmonary infections, and bloodstream infections. The IND approval allows the company to proceed with clinical development of TUL108 in the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL1VcBwK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"gpt_icon":0},{"id":"1103254930","title":"Federal Pharmaceutical (03933): Injection TUL108 Receives FDA Approval for New Drug Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1103254930","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103254930?lang=en_us&edition=fundamental","pubTime":"2026-01-28 19:27","pubTimestamp":1769599633,"startTime":"0","endTime":"0","summary":"Federal Pharmaceutical (03933) announced that on January 28, 2026, the Investigational New Drug (IND) application for its Class 1 innovative drug, Injection TUL108, independently developed by its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2606900677","title":"United Laboratories International - FDA Approves Ind for United Lab's Tul108 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2606900677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606900677?lang=en_us&edition=fundamental","pubTime":"2026-01-28 19:17","pubTimestamp":1769599056,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT0CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2604186705","title":"Investors in United Laboratories International Holdings (HKG:3933) have seen impressive returns of 175% over the past three years","url":"https://stock-news.laohu8.com/highlight/detail?id=2604186705","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604186705?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:52","pubTimestamp":1768783964,"startTime":"0","endTime":"0","summary":"It hasn't been the best quarter for The United Laboratories International Holdings Limited ( HKG:3933 ) shareholders...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/investors-in-united-laboratories-international-holdings-hkg3-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/investors-in-united-laboratories-international-holdings-hkg3-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK1191","BK4211","03933"],"gpt_icon":0},{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","LU0106261372.USD","03692","IE00BJLML261.HKD","LU0211328371.USD","MTSR","BK0188","VKTX","LLY","LU0345777147.USD","SG9999014906.USD","IE00B4JS1V06.HKD","AMGN","IE00BN8TJ469.HKD","OPK","SGXZ99366536.SGD","IE0005OL40V9.USD","BK0028","IE00BJJMRX11.SGD","LU0499090636.EUR","LU1720051017.SGD","LU1035775433.USD","00656","SG9999013999.USD","BK0187","LU2106854487.HKD","LU0823434583.USD","LU1003077747.HKD","LU0256863902.USD","AZN.UK","LU1989772840.SGD","LU0130517989.USD","MRK","LU0306806265.USD","03933","ALT","LU1989771016.USD","IE0002141913.USD","IE00BK4W5M84.HKD","LU1323610961.USD","LU1061106388.HKD","03165","02105","SG9999015986.USD","SRRK","LU0964806797.USD","BK4566","GPCR","SG9999002224.SGD"],"gpt_icon":1},{"id":"2590312981","title":"BRIEF-United Laboratories International Says Unit's Levofloxacin Eye Drops Approved By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590312981","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590312981?lang=en_us&edition=fundamental","pubTime":"2025-12-09 18:09","pubTimestamp":1765274969,"startTime":"0","endTime":"0","summary":"BRIEF-United Laboratories International Says Unit's Levofloxacin Eye Drops Approved By NMPADec 9 (Reuters) - United Laboratories International Holdings Ltd 3933.HK:LEVOFLOXACIN EYE DROPS SUBMITTED BY UNIT APPROVED BY NMPAFurther company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"gpt_icon":0},{"id":"1102141054","title":"UNITED LAB (03933): Levofloxacin Eye Drops Approved for Market by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1102141054","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102141054?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:58","pubTimestamp":1765274302,"startTime":"0","endTime":"0","summary":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2590266314","title":"United Laboratories International -  Levofloxacin Eye Drops Submitted by Unit Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590266314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590266314?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:53","pubTimestamp":1765274020,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2590331442","title":"TUL Wins China Approval for Levofloxacin Eye Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2590331442","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590331442?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:53","pubTimestamp":1765273988,"startTime":"0","endTime":"0","summary":"The United Laboratories International Holdings Ltd.  announced that its subsidiary, Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, has received regulatory approval from the China National Medical Products Administration for its Levofloxacin Eye Drops , with drug approval number H20256135. This approval expands TUL's ophthalmic drug portfolio and solidifies its position in the field of ophthalmic anti-infective treatment. The product is also included in the Category A of the National Medical Insurance Drug List . There is no indication that grant funding or regulatory approval was obtained by organizations other than TUL.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL9MNMtJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2589805306","title":"The Bull Case For United Laboratories International Holdings (SEHK:3933) Could Change Following Key Cefoperazone-Sulbactam Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2589805306","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589805306?lang=en_us&edition=fundamental","pubTime":"2025-12-07 22:17","pubTimestamp":1765117078,"startTime":"0","endTime":"0","summary":"United Laboratories International Holdings recently reported that its wholly owned Zhongshan branch of Zhuhai United Laboratories received China National Medical Products Administration approval, with quality and efficacy consistency evaluation, for its 2.0g Cefoperazone Sodium and Sulbactam Sodium for Injection, already classified as a Category B drug in the 2024 National Medical Insurance Drug List.\nThis outcome strengthens the company’s anti-infective portfolio by validating a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/the-bull-case-for-united-laboratories-international-holdings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/the-bull-case-for-united-laboratories-international-holdings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UBCP","BK1191","BK4211","03933"],"gpt_icon":0},{"id":"2589482630","title":"United Laboratories (SEHK:3933): Evaluating a Low P/E Valuation After New China Drug Consistency Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2589482630","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589482630?lang=en_us&edition=fundamental","pubTime":"2025-12-06 17:20","pubTimestamp":1765012828,"startTime":"0","endTime":"0","summary":"United Laboratories International Holdings (SEHK:3933) just cleared a meaningful regulatory hurdle, with its subsidiary’s Cefoperazone and Sulbactam injection passing China’s consistency evaluation, reinforcing its anti infective franchise and long term growth platform.\nSee our latest analysis for United Laboratories International Holdings.\nDespite the setback of a roughly 27 percent 3 month share price return, the stock has still delivered a strong 1 year total shareholder return near 20...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-sehk3933-evaluating-a-low-pe-valuation-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-sehk3933-evaluating-a-low-pe-valuation-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK1191","03933","UBCP","DCF"],"gpt_icon":0},{"id":"1156292861","title":"The United Laboratories (03933) Announces Monthly Share Capital Return: Authorized Capital and Issued Shares Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=1156292861","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156292861?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:24","pubTimestamp":1764753887,"startTime":"0","endTime":"0","summary":"The United Laboratories International Holdings Limited (stock code: 03933) has released its Monthly Return for Equity Issuer for the period ended 30 November 2025. According to the announcement, the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"gpt_icon":0},{"id":"2587586731","title":"Why United Laboratories (SEHK:3933) Is Up 8.8% After Landmark Drug Approval in China and What’s Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2587586731","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587586731?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:24","pubTimestamp":1764339859,"startTime":"0","endTime":"0","summary":"United Laboratories International Holdings recently announced that its Cefoperazone Sodium and Sulbactam Sodium for Injection has passed the consistency evaluation by the China National Medical Products Administration.\nThis achievement marks a significant regulatory milestone and highlights the company's ongoing focus on expanding its anti-infective product portfolio through research and development.\nWe'll explore how this successful product evaluation strengthens United Laboratories'...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/why-united-laboratories-sehk3933-is-up-88-after-landmark-dru","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/why-united-laboratories-sehk3933-is-up-88-after-landmark-dru","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["03933","BK4211","LARK","UBCP","BK1191"],"gpt_icon":0},{"id":"2586255603","title":"Update: The United Laboratories Unit's Antibiotic Passes Chinese Regulator's Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586255603","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586255603?lang=en_us&edition=fundamental","pubTime":"2025-11-26 18:42","pubTimestamp":1764153765,"startTime":"0","endTime":"0","summary":"The United Laboratories International  said Cefoperazone Sodium and Sulbactam Sodium for Injection passed China National Medical Products Administration's consistency evaluation, a Wednesday Hong Kong bourse filing said.The drug was submitted by the Zhongshan Branch of Zhuhai United Laboratories, a unit of the firm.The drug is a cephalosporin antibiotic which, when used as monotherapy, is indicated for the treatment of various infections, including respiratory tract infections, urinary tract infections, meningitis, and genital tract infections.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","03933","UBCP","BK4211"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":-0.0117},{"period":"3month","weight":-0.0699},{"period":"6month","weight":-0.2077},{"period":"1year","weight":0.0644},{"period":"ytd","weight":0.0224}],"compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0136},{"period":"6month","weight":0.08},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"The United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.033088},{"month":2,"riseRate":0.684211,"avgChangeRate":0.070916},{"month":3,"riseRate":0.666667,"avgChangeRate":0.040428},{"month":4,"riseRate":0.611111,"avgChangeRate":0.081119},{"month":5,"riseRate":0.666667,"avgChangeRate":0.040685},{"month":6,"riseRate":0.277778,"avgChangeRate":-0.012388},{"month":7,"riseRate":0.526316,"avgChangeRate":0.011895},{"month":8,"riseRate":0.473684,"avgChangeRate":0.025474},{"month":9,"riseRate":0.421053,"avgChangeRate":-0.006971},{"month":10,"riseRate":0.631579,"avgChangeRate":-0.000903},{"month":11,"riseRate":0.473684,"avgChangeRate":-0.023163},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011153}],"exchange":"SEHK","name":"UNITED LAB","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"UNITED LAB(03933),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest UNITED LAB(03933) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"UNITED LAB,03933,UNITED LAB股票,UNITED LAB股票老虎,UNITED LAB股票老虎国际,UNITED LAB行情,UNITED LAB股票行情,UNITED LAB股价,UNITED LAB股市,UNITED LAB股票价格,UNITED LAB股票交易,UNITED LAB股票购买,UNITED LAB股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"UNITED LAB(03933),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest UNITED LAB(03933) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}